Immune
Thymosin Alpha-1
28-amino-acid immunomodulator marketed globally as Zadaxin for hepatitis and adjunct oncology use.
- Half-life
- ~2 hours
- Route
- Subcutaneous
Overview
Thymosin alpha-1 (Tα1) is a naturally occurring polypeptide derived from prothymosin alpha. Approved in over 35 countries for hepatitis B and C and as an adjunct in immune-compromised states.
Mechanism of action
Activates toll-like receptor 9 on plasmacytoid dendritic cells, restores T-cell function, modulates cytokine balance and enhances NK-cell activity.
Evidence base
Randomised trials support use in chronic hepatitis B and as an adjuvant to interferon in hepatitis C. Studied during COVID-19 for prevention of lymphopenia in severe cases.
Typical dosing
Common protocol: 1.6 mg subcutaneously twice weekly for 6–12 months in chronic viral hepatitis. Longevity protocols often use 450–900 mcg twice weekly. Open the dose calculator →
Safety & contraindications
Excellent tolerability profile across decades of use. Caution in solid-organ transplant recipients due to immune-activating effect.
Educational reference only. Nothing on this page is medical advice, a prescription, or an offer to sell. Discuss any peptide therapy with a qualified clinician who can evaluate your history and monitoring needs.